通过皮下注射单克隆抗体来预防疟疾
Kassoum Kayentao1, Aissata Ongoiba1, Anne C Preston1
1From the Malaria Research and Training Center, Mali International Center of Excellence in Research, University of Sciences, Techniques, and Technologies of Bamako, Bamako, Mali (K.K., A. Ongoiba, S.D., D.D., A.T., H.T., A. Djiguiba, S. Traore, M.K., A.Z., A. Ouattara, M.D., A. Dolo, A. Djimdé, B.T.); the Malaria Infection Biology and Immunity Section, Laboratory of Immunogenetics, Division of Intramural Research (A.C.P., S.A.H., J.S., H.C., S.L., M.E.P., P.D.C.), and the Biostatistics Research Branch, Division of Clinical Research (Z.H.), National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, the Vaccine Research Center (S. Telscher, A.H.I., W.C.A., A.B.M., S.N., B.C.L., L.S., S.P.H., A.J.M., S.V., M.R., J.A.S., J.G.G., K.C., R.A.S.), National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, and the Clinical Monitoring Research Program Directorate, Frederick National Laboratory for Cancer Research, Frederick (J.W.) - all in Maryland; the Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston (P.S., D.E.N.); the Malaria Molecular Diagnostic Laboratory, Department of Laboratory Medicine and Pathology, and the Center for Emerging and Re-emerging Infectious Diseases, University of Washington, Seattle (S.C.M.); and the Max Planck Institute for Infection Biology, Berlin (S.P.).
皮下L9LS单克隆抗体安全地保护了马里的儿童免受疟疾的侵害. 在六个月的时间里,治疗显著减少了Plasmodium falciparum感染和临床疟疾.
科学领域:
- 免疫学 免疫学 免疫学
- 传染性疾病 传染性疾病
- 儿科 儿科 儿科
背景情况:
- 单克隆抗体为预防疟疾提供了潜力.
- 之前的研究表明,皮下L9LS保护了成年人免受Plasmodium falciparum.
- 在特有儿科患者群体中,疗效和安全性仍未确立.
研究的目的:
- 评估马里6-10岁儿童皮下L9LS的安全性和有效性.
- 在6个月的时间内评估对Plasmodium falciparum感染和临床疟疾的保护.
主要方法:
- 第二阶段临床试验涉及马里225名儿童.
- 随机,双盲,安慰剂控制的设计,使用150毫克或300毫克的L9LS剂量,或安慰剂.
- 主要终点:通过血液涂抹检测到第一个P.falciparum感染的时间;次要终点:第一个临床疟疾发作的时间.
主要成果:
- 在任何治疗组中都没有发现安全问题.
- 与安慰剂相比,L9LS显示出显著的疗效:P. falciparum感染的66-70%减少和临床疟疾的67-77%减少.
- 对150毫克和300毫克剂量均观察到有效性.
结论:
- 皮下L9LS是一种安全有效的干预措施,用于预防P. falciparum感染和儿童的临床疟疾.
- 这些发现支持L9LS作为流行地区疟疾控制的有希望的工具.
- 进一步的研究可能会探索长期疗效和更广泛的实施策略.
更多相关视频
10:38High Yield Purification of Plasmodium falciparum Merozoites For Use in Opsonizing Antibody Assays
Published on: July 17, 2014
08:46Myeloid Cell Isolation from Mouse Skin and Draining Lymph Node Following Intradermal Immunization with Live Attenuated Plasmodium Sporozoites
Published on: May 18, 2016
